New drug target identified for myelodysplastic syndrome
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
List view / Grid view
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
A screening campaign has revealed that small molecule inhibitors of the SOX 11 oncogene are toxic to mantle cell lymphoma in vitro.
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
The loss of RXR function, a molecular mechanism which determines the identity macrophages, has been revealed as a drug target for cancers in serous cavities.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.